APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

$47.02  +0.54 (1.16%)
As of 05/07/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/09/2017
Outstanding shares:  80,496,771
Average volume:  686,712
Market cap:   $3,741,489,916
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03753U106
ISIN:        US03753U1060
Sedol:      BYTQ6X1
Valuation   (See tab for details)
PE ratio:   -65.97
PB ratio:   73.32
PS ratio:   14.93
Return on equity:   -696.33%
Net income %:   -143.51%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy